Renal regulation

Renal Atheroembolism

Renal biopsy

Renal disease

Renal disorders

Renal impairment in mutiple myeloma

Renal impairment is a common complication in multiple myeloma (MM). It is seen in 20-40% of patients with MM. In about 5% of cases, acute renal impairment occurs, which is oliguric and may require hae...

Linagliptin effective in type 2 diabetics with severe renal impairment

NEW YORK (Reuters Health) - Linagliptin improves glycemic control in type 2 diabetics with severe renal impairment, with no extra risk of hypoglycemia.

World's No 1 blood pressure med goes generic in US

The US patent on best-selling antihypertensive valsartan and the combination product valsartan plus the diuretic hydrochlorothiazide ( Novartis's Diovan/Diovan HCT) expired on Friday, and Mylan has l...

Results Preview: Diovan loss will hurt Novartis in ‘a year of two halves’

As investors settle in to a 'post-Diovan' Novartis, it is likely that the company's full-year 2012 results, due 23 January, will be well-received despite the lower sales. The patent covering Diovan, t...

Use enoxaparin with caution in renal impairment: study

NEW YORK (Reuters Health) - Enoxaparin (Lovenox) increases the risk of major bleeding in patients with moderate renal impairment, according to a retrospective study from the Minneapolis Veterans A...

Immune cell dysfunction and inflammation in end-stage renal disease

Loss of renal function is associated with inflammation and immune system impairment, which results in an increased susceptibility to viral and bacterial infections, poor vaccination responses and an i...

Mylan sues FDA as Ranbaxy's Diovan fails to materialise

Mylan has filed suit against the US FDA, after the agency blocked it from launching its own generic version of Novartis's blockbuster blood pressure medication Diovan (valsartan) even though the holde...

Filtering out the key issues in renal medicine

The kidneys, as an organ, exerts enormous influence over the body, thus renal-malfunction is an important condition to treat. Filtering the key issues of renal medicine and these are the main topics...

Effect of Hepatic or Renal Impairment on Eltrombopag Pharmacokinetics.

Eltrombopag, an oral, small-molecule, nonpeptide thrombopoietin receptor agonist for the treatment of thrombocytopenia, is highly protein bound and primarily eliminated via metabolism in the liver and...

Effect of hepatic or renal impairment on the pharmacokinetics of casopitant, a NK-1 receptor antagonist.

Two studies were conducted in subjects with mild or moderate hepatic or renal impairment and subjects with normal organ function to evaluate the pharmacokinetics of casopitant and to assess its safety...

Severe renal impairment and stroke prevention in atrial fibrillation implications for thromboprophylaxis and bleeding risk.

The prevalence of atrial fibrillation (AF) in end-stage renal failure is high, with an increased risk of stroke among these patients with AF compared with the AF population without severe renal impair...

Effect of Renal Impairment on the Pharmacokinetics of the Dipeptidyl Peptidase-4 Inhibitor Linagliptin.

Aim: This study assessed the influence of various degrees of renal impairment on the exposure of linagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor with a primarily non-renal route of excretion,...

Pharmacokinetics of teduglutide in subjects with renal impairment.

PURPOSE: Teduglutide is a recombinant analogue of human glucagon-like peptide-2 that has recently been approved for the treatment of short bowel syndrome in adults. This study was designed to study th...